H2O

Phase 2Small molecule

MMontefiore Medical Center

H2O is one of 15 small molecule programs targeting Von Hippel-Lindau Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Von Hippel-Lindau DiseaseActive, not recruiting

Von Hippel-Lindau DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

15 competitors in Von Hippel-Lindau Disease

#DrugCompanyPhaseTrials

Afinitor

Novartis

Phase 3

1 2

Cabometyx

Bristol-Myers Squibb

Phase 3

1 3

Ibrance

Pfizer

Phase 3

1 4

Opdivo

Bristol-Myers Squibb

Phase 3

1 5

Lenvima

Eisai

Phase 3

1 6

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 7

Sutent

TKI258

Lucentis

1 10

Macugen

Pfizer

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Clinical Trial1 trial

Clinical Trial Comparing Two Protocols Using Intravenous (IV) Hydromorphone

Completed·MMontefiore Medical Center·Phase 3·NCT01311895·350 enrolled

Von Hippel-Lindau Disease1 trial

17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00088374·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for H2O. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — H2O compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for H2O. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Montefiore Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMontefiore Medical Center

H2O

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Clinical Trial1 trial

Von Hippel-Lindau Disease1 trial

References

Drug Info

Quick Facts

Related News